Intermountain Healthcare and deCODE genetics Launch Groundbreaking DNA Study of 500,000 People to Find New Links Between Genetics and Disease

Study Represents Largest DNA Mapping Effort Undertaken in U.S.
From a Single Population

REYKJAVIK, Iceland & SALT LAKE CITY–(BUSINESS WIRE)–#Healthcare–Intermountain Healthcare and deCODE genetics have announced a major
global collaboration and study focused on discovering new connections
between genetics and human disease that will involve the collection of
half a million DNA samples.

The initiative, called the HerediGene: Population Study, represents the
largest and most comprehensive DNA mapping effort to date in the United
States from a single population. For the study, which is voluntary and
free to participants, Intermountain teams will work with deCODE to
analyze the genomes of 500,000 people from Intermountain’s patient
population, primarily in Utah and Idaho.

Intermountain Healthcare is a Utah-based not-for-profit integrated
healthcare delivery network, and deCODE genetics is a wholly owned
subsidiary of Amgen based in Reykjavik, Iceland. The collaborative
effort combines Intermountain’s internationally-recognized expertise in
precision medicine and clinical care with deCODE’s world-class expertise
in human population genetics.

“While the 500,000 samples will be collected primarily from patients in
Utah, the research is expected to have a global impact as medications,
treatments, and healthcare innovations that can benefit patients
universally are developed from the findings,” said Lincoln Nadauld, MD,
PhD, Intermountain’s chief of precision health. “The collaboration is
noteworthy and unique in its size, scope, and immediate application to
patient care.”

Participants in the study will consent to the testing and have the
option to receive their genetic results report, if a clinically
significant gene mutation is identified. The data will be de-identified
to ensure anonymity before it is utilized in research to help medical
professionals better understand the human genome, which will enhance
their ability to predict and prevent diseases such as breast cancer,
colon cancer, and heart disease.

“This unique collaboration is expected to uncover new insights into some
of society’s most debilitating diseases,” noted Kári Stefánsson, MD, Dr.
Med., founder and chief executive officer of deCODE genetics. “Our
partnership with Intermountain Healthcare is important as we continue to
identify and validate human disease targets. These potential discoveries
will allow deCODE and Amgen to rapidly develop new medicines that reach
the right disease targets.”

Intermountain will leverage its renowned precision genomics efforts to
improve patient outcomes and transform medicine. Intermountain’s
precision medicine team analyzes individual differences in genetics,
environments, and lifestyles and helps medical professionals
specifically target the illnesses of each patient and identify the
treatments that will best help them.

“Better health and being able to cure common diseases is the promise of
precision medicine, but it’s not happening fast enough,” said Marc
Harrison, MD, president and chief executive officer at Intermountain
Healthcare. “For too long, the genetic code to better health has been
locked. This collaboration with deCODE unlocks that insight so we can
rapidly advance well-being – not only for ourselves and our families,
but for generations to come.”

Insights from the collaboration may power fundamental changes to better
understand the human genome, improve health, and prevent common diseases.

For more information on the study, please go to

About deCODE genetics

Based in Reykjavik, Iceland, deCODE is a global leader in analyzing and
understanding the human genome. Using its unique expertise and
population resources, deCODE has discovered genetic risk factors for
dozens of common diseases. Understanding the genetics of disease can
create new means of diagnosing, treating and preventing disease. deCODE
is a wholly-owned subsidiary of Amgen.

About Intermountain

Intermountain Healthcare is a Utah-based not-for-profit system of 24
hospitals, 160 clinics, a Medical Group with some 2,300 employed
physicians and advanced care practitioners, a health insurance company
called SelectHealth, and other health services. Intermountain is widely
recognized as a leader in transforming healthcare through evidence-based
best practices, high quality, and sustainable costs. For more
information about Intermountain, visit

Amgen Forward-Looking Statements

This news release contains forward-looking statements that are based on
the current expectations and beliefs of Amgen. All statements, other
than statements of historical fact, are statements that could be deemed
forward-looking statements, including estimates of revenues, operating
margins, capital expenditures, cash, other financial metrics, expected
legal, arbitration, political, regulatory or clinical results or
practices, customer and prescriber patterns or practices, reimbursement
activities and outcomes and other such estimates and results.
Forward-looking statements involve significant risks and uncertainties,
including those discussed below and more fully described in the
Securities and Exchange Commission reports filed by Amgen, including its
most recent annual report on Form 10-K and any subsequent periodic
reports on Form 10-Q and current reports on Form 8-K. Unless otherwise
noted, Amgen is providing this information as of the date of this news
release and does not undertake any obligation to update any
forward-looking statements contained in this document as a result of new
information, future events or otherwise.

No forward-looking statement can be guaranteed, and actual results may
differ materially from those Amgen project. Amgen’s results may be
affected by its ability to successfully market both new and existing
products domestically and internationally, clinical and regulatory
developments involving current and future products, sales growth of
recently launched products, competition from other products including
biosimilars, difficulties or delays in manufacturing its products and
global economic conditions. In addition, sales of Amgen’s products are
affected by pricing pressure, political and public scrutiny and
reimbursement policies imposed by third-party payers, including
governments, private insurance plans and managed care providers and may
be affected by regulatory, clinical and guideline developments and
domestic and international trends toward managed care and healthcare
cost containment. Furthermore, Amgen’s research, testing, pricing,
marketing and other operations are subject to extensive regulation by
domestic and foreign government regulatory authorities. Amgen or others
could identify safety, side effects or manufacturing problems with its
products, including its devices, after they are on the market. Amgen’s
business may be impacted by government investigations, litigation and
product liability claims. In addition, Amgen’s business may be impacted
by the adoption of new tax legislation or exposure to additional tax
liabilities. If we fail to meet the compliance obligations in the
corporate integrity agreement between us and the U.S. government, we
could become subject to significant sanctions. Further, while Amgen
routinely obtains patents for its products and technology, the
protection offered by its patents and patent applications may be
challenged, invalidated or circumvented by its competitors, or Amgen may
fail to prevail in present and future intellectual property litigation.
Amgen performs a substantial amount of its commercial manufacturing
activities at a few key facilities, including in Puerto Rico, and also
depends on third parties for a portion of its manufacturing activities,
and limits on supply may constrain sales of certain of its current
products and product candidate development. In addition, Amgen competes
with other companies with respect to many of its marketed products as
well as for the discovery and development of new products. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement from
concept to product is uncertain; consequently, there can be no guarantee
that any particular product candidate or development of a new indication
for an existing product will be successful and become a commercial
product. Further, some raw materials, medical devices and component
parts for Amgen’s products are supplied by sole third-party suppliers.
Certain of Amgen’s distributors, customers and payers have substantial
purchasing leverage in their dealings with Amgen. The discovery of
significant problems with a product similar to one of Amgen’s products
that implicate an entire class of products could have a material adverse
effect on sales of the affected products and on its business and results
of operations. Amgen’s efforts to acquire other companies or products
and to integrate the operations of companies Amgen has acquired may not
be successful. A breakdown, cyberattack or information security breach
could compromise the confidentiality, integrity and availability of
Amgen’s systems and Amgen’s data. Amgen’s stock price may be volatile
and may be affected by a number of events. Amgen’s business performance
could affect or limit the ability of the Amgen Board of Directors to
declare a dividend or its ability to pay a dividend or repurchase its
common stock. Amgen may not be able to access the capital and credit
markets on terms that are favorable to it, or at all.

The scientific information discussed in this news release related to
Amgen’s product candidates is preliminary and investigative. Such
product candidates are not approved by the U.S. Food and Drug
Administration, and no conclusions can or should be drawn regarding the
safety or effectiveness of the product candidates. Further, the
scientific information discussed in this news release relating to new
indications for Amgen’s products is preliminary and investigative and is
not part of the labeling approved by the U.S. Food and Drug
Administration for the products. The products are not approved for the
investigational use(s) discussed in this news release, and no
conclusions can or should be drawn regarding the safety or effectiveness
of the products for these uses.


Media Contacts:
Intermountain Healthcare:
Brad Gillman:

deCODE genetics:
Jon Gustafsson:
664 1905

Leave a Reply

Sky Optics Media drone video